{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:23:03Z","timestamp":1781904183940,"version":"3.54.5"},"reference-count":41,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T00:00:00Z","timestamp":1469923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast majority of basal cell carcinomas (BCCs). There are two United States Food and Drug Administration (US FDA)-approved Hh pathway inhibitors (HPIs) that exhibit antitumor activity in advanced BCC with an acceptable safety profile. Common adverse effects include muscle spasms, dysgeusia, alopecia, fatigue, nausea and weight loss.<\/jats:p>","DOI":"10.1177\/1758834016653605","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T20:36:19Z","timestamp":1467318979000},"page":"375-382","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":40,"title":["Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness"],"prefix":"10.1177","volume":"8","author":[{"given":"Sirunya","family":"Silapunt","sequence":"first","affiliation":[{"name":"Department of Dermatology, the University of Texas McGovern Medical School at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Migden","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1452, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,31]]},"reference":[{"key":"bibr1-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13630"},{"key":"bibr2-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1937"},{"key":"bibr3-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00222.x"},{"key":"bibr4-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.002"},{"key":"bibr5-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.1998.9103"},{"key":"bibr6-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5369.1603"},{"key":"bibr7-1758834016653605","author":"Danial C.","year":"2015","journal-title":"Clin Cancer Res"},{"key":"bibr8-1758834016653605","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.50"},{"key":"bibr9-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"bibr10-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2503"},{"key":"bibr11-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1038\/ng0996-78"},{"key":"bibr12-1758834016653605","unstructured":"Genentech, Inc. (2012) Erivedge (Vismodegib) Package Insert. San Francisco, CA: Genentech, Inc."},{"key":"bibr13-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81268-4"},{"key":"bibr14-1758834016653605","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1242\/dev.125.18.3553","volume":"125","author":"Incardona J.","year":"1998","journal-title":"Development"},{"key":"bibr15-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5268.1668"},{"key":"bibr16-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00822.2014"},{"key":"bibr17-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2932-1"},{"key":"bibr18-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2745"},{"key":"bibr19-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0972"},{"key":"bibr20-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61196-X"},{"key":"bibr21-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70100-2"},{"key":"bibr22-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-014-0069-y"},{"key":"bibr23-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70260-2"},{"key":"bibr24-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1038\/287795a0"},{"key":"bibr25-1758834016653605","unstructured":"Novartis Pharmaceuticals Corp. (2015) Odomzo (Sonidegib) Package Insert. East Hanover, NJ: Novartis Pharmaceuticals Corp."},{"key":"bibr26-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2007.06.002"},{"key":"bibr27-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1021\/ml1000307"},{"key":"bibr28-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1710"},{"key":"bibr29-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/j.mod.2004.10.002"},{"key":"bibr30-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.021."},{"key":"bibr31-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113713"},{"key":"bibr32-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.02.001"},{"key":"bibr33-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.48"},{"key":"bibr34-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1038\/384129a0"},{"key":"bibr35-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.09.021"},{"key":"bibr36-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"bibr37-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905360"},{"key":"bibr38-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1021\/ol900974u"},{"key":"bibr39-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1038\/34201"},{"key":"bibr40-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.350"},{"key":"bibr41-1758834016653605","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2468-y"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1758834016653605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1758834016653605","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1758834016653605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:21:32Z","timestamp":1777587692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1758834016653605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,31]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1177\/1758834016653605"],"URL":"https:\/\/doi.org\/10.1177\/1758834016653605","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,31]]}}}